CARM (CARISMA Therapeutics) GF Score : 14/100 (As of Dec. 15, 2024)

View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics GF Score?

CARISMA Therapeutics has the GF Score of 14, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes CARISMA Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of CARISMA Therapeutics's GF Score

For the Biotechnology subindustry, CARISMA Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's GF Score falls into.

CARISMA Therapeutics (NAS:CARM) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

CARISMA Therapeutics GF Score Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

CARISMA Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (NAS:CARM) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

W2J:Germany

Address

3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104

Website

https://www.carismatx.com

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

Executives

Modernatx, Inc.	10 percent owner	200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Sanford S Zweifach	director	21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Steven Kelly	director, officer: President and CEO	C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Briggs Morrison	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Richard Steven Morris	officer: Chief Financial Officer	397 EAGLEVIEW BOULEVARD, EXTON PA 19341
Chidozie Ugwumba	director	158 FILMORE STREET, DENVER CO 80206
Michael Klichinsky	officer: Chief Scientific Officer	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Michael Torok	director	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Regina Hodits	director	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bjorn Odlander	director	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Minori Rosales	officer: Chief Development Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Jewett Michael A. S.	director	C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Peter Honig	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Patricia M. Drake	officer: Chief Commercial Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Elly Ryu	officer: Principal Accounting Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142